Drug Trial Radar · NCT05613088
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
106
Actual
Start
Feb 1, 2023
Primary completion
Jun 17, 2024
Study completion Sep 10, 2025
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Eisai Inc.
- First posted
- Nov 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Conditions
- Neoplasms, Ovarian
Interventions
MORAb-202Drug
Specified dose on specified days
PaclitaxelDrug
Specified dose on specified days
Pegylated Liposomal Doxorubicin (PLD)Drug
Specified dose on specified days
TopotecanDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator AssessmentTime frame: From the date of randomization to the date of first objectively-documented progression or the date of subsequent therapy (Up to approximately 70 weeks)
- Number of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First DoseTime frame: From first dose of study medication up to 6 months
Locations
50 sites in 9 countries. Site status is shown where the registry gives one.
Local Institution - 0065
Sacramento, California
Local Institution - 0025
San Francisco, California
Local Institution - 0078
Whittier, California
Local Institution - 0081
South Bend, Indiana
Local Institution - 0043
Kansas City, Kansas
Local Institution - 0023
Canton, Ohio
Local Institution - 0061
Columbus, Ohio
Local Institution - 0044
Nashville, Tennessee
Local Institution - 0082
Salt Lake City, Utah
Local Institution - 0042
Spokane, Washington
Local Institution - 0016
Sydney, New South Wales, Australia
Local Institution - 0017
Waratah, New South Wales, Australia
Local Institution - 0031
Chermside, Queensland, Australia
Local Institution - 0015
Clayton, Victoria, Australia
Local Institution - 0027
Malvern, Victoria, Australia
Local Institution - 0058
Nedlands, Western Australia, Australia
Local Institution - 0012
Brussels, Belgium
Local Institution - 0045
Liège, Belgium
Local Institution - 0032
Leuven, VBR, Belgium
Local Institution - 0013
Namur, WNA, Belgium
Local Institution - 0036
Santiago, Chile
Local Institution - 0029
Temuco, Chile
Local Institution - 0030
Santiago, RM, Chile
Local Institution - 0054
Haifa, Israel
Local Institution - 0080
Jerusalem, Israel
Local Institution - 0055
Ramat Gan, Israel
Local Institution - 0048
Tel Aviv, Israel
Local Institution - 0046
Jerusaelm, JM, Israel
Local Institution - 0002
Brescia, Italy
Local Institution - 0003
Bologna, BO, Italy
Local Institution - 0011
Milan, MI, Italy
Local Institution - 0009
Milan, MI, Italy
Local Institution - 0010
Roma, RM, Italy
Local Institution - 0018
Akashi, Hyogo, Japan
Local Institution - 0019
Chūōku, Japan
Local Institution - 0014
Hidaka-shi, Japan
Local Institution - 0004
Kurume-Shi, Japan
Local Institution - 0037
Tokyo, Japan
Local Institution - 0056
Seoul, South Korea
Local Institution - 0049
Seoul, South Korea
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.